Licensed Patent. Subject to the terms and conditions of this Agreement, the University hereby grants to the Licensee an Exclusive license (sub-licensable if Section 7 of the EPLA is marked "Yes") under the Licensed Patent in the Field of Use to make, have made, use, import, offer to sell and sell Licensed Product in the Territory.
Licensed Patent. Licensed Patent" as used in this Agreement shall mean claims derived from United States Patent No. 10000023, and any patent issued in the future from any reissue, reexamination, divisional, continuation, and/or continuation-in-part of the Licensed Patents, including any foreign counterpart thereof.
Licensed Patent. Jackxxx xxxeby grants to Argonaut a worldwide Field exclusive, sub-licensable, worldwide license, under the Licensed Patent, to develop, manufacture, have manufactured, modify, use, market, service, sell and otherwise distribute the Products. Jackxxx xxxerves the right to practice under the Patent solely for its own research purposes.
Licensed Patent. Licensed Patent" as used in this Agreement shall mean claims derived from Xxxx Xxxxxxxx et. al, "Enhanced Metal Matrix Composite Weapon Barrels", U.S. Patent # 10718586, as assigned to Consulting Group of Jocassee, Inc. on 28 May 2019, and any patent issued in the future from any reissue, reexamination, divisional, continuation, and/or continuation-in-part of the Licensed Patents, including any foreign counterpart thereof.
Licensed Patent. The Licensed Patent is a patent for invention registered in the PRC for certain steel cord constructions. Tengzhou Eastern and Jiaxing Eastern have applied the Licensed Patent in the Licensed Products manufactured in their respective plants in operation.
Licensed Patent. (s) shall mean
a) the following patent applications and patents relating to ganglioside vaccines, intermediates or methods of producing them, or methods of, or compositions using, them which are owned by LICENSOR [***]
(i) U.S. Patent Application No. 08/009,268 (Filed January 22, 1993) all patents issuing therefrom and all divisions, continuations, reissues, substitutes, and extensions thereof and the foreign equivalents thereof; [***]
(ii) all patents and patent applications, whether filed before or after the EFFECTIVE DATE of this Agreement, which claim priority under 35 U.S.C. Sec. 119 or the benefit of the filing date under 35 U.S.
Licensed Patent. (s) shall mean
a) the following patent applications and patents relating to ganglioside vaccines, intermediates or methods of producing them, or methods of, or compositions using, them which are owned by LICENSOR [***]
(i) U.S. Patent Application No. 08/009,268 (Filed January 22, 1993) all patents issuing therefrom and all divisions, continuations, reissues, substitutes, and extensions thereof and the foreign equivalents thereof; [***] [***]
Licensed Patent. A Licensed Patent shall include the patents and patents issuing from the patent applications listed in Exhibit A hereto, including any continuations, divisionals or reissues and including any improvements by Yu.
Licensed Patent. Licensee shall have no right to enforce the Licensed Patent against any third party.
E. The Parties agree to take reasonable steps to ensure the confidentiality of the terms of this Agreement and, accordingly, any release of information relating to this Agreement must be reviewed and approved in advance by each of the Parties, except that copies of this Agreement may be made available to government agencies in compliance with regulations thereof requiring the disclosure of material agreements. Neither party shall be liable for disclosure of the terms of this Agreement if made in response to a valid order of a court or authorized agency of government; provided that ten (10) days' notice first be given to the other part so a protective order, if appropriate, may be sought by such party. Furthermore, either party may disclose, in confidence, the terms of this Agreement to its financial consultants, tax planners and/or advisors, attorneys, underwriters, and/or third parties under an obligation to the disclosing party to preserve the secrecy of the disclosing party's confidential information, without the consent of the other party. Anything to the contrary notwithstanding, Licensor may disclose the terms of this Agreement under suitable confidentiality terms in connection with further licensing of the Licensed Patent.
F. The Parties shall cooperate in reasonable efforts to publicize the '829 Patent through the joint dissemination of a press release in a form substantially similar to that attached hereto within sixty (60) days of the Effective Date. Nothing herein shall preclude further announcements by the Parties.
Article V - Marking Licensee shall mark xxx prominently display the legend "U.S. Patent 4,839,829" on all literature, users manuals and documentation produced that promotes the system under the Licensed Patent and on all web sites that promote or feature the system of the License Patent. Furthermore, Licensee must prominently list the Licensed Patent as licensed from Henrx X. Xxxxxxxx xxx must prominently list the web site and telephone number of Henrx X. Xxxxxxxx xx the owner of the Licensed Patent on Licensee's Internet web site.
Licensed Patent. Subject to the other terms and conditions of this Agreement, the Licensor hereby grants, and Ellipsis hereby accepts, a worldwide license, with the right to grant sublicenses, in all fields of use, to make, have made, use and sell Diagnostic Royalty Products and Therapeutic Royalty Products, and to grant sublicenses with respect to the Licensed Patent.
